Y-mAbs Therapeutics (NASDAQ:YMAB) Earns Outperform Rating from Wedbush

Wedbush reiterated their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a report released on Monday morning,RTT News reports. Wedbush currently has a $23.00 target price on the stock.

Several other brokerages also recently weighed in on YMAB. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, January 13th. Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target for the company. Finally, Oppenheimer started coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Y-mAbs Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $19.30.

Y-mAbs Therapeutics Stock Performance

NASDAQ YMAB opened at $4.85 on Monday. The firm’s 50 day moving average price is $6.46 and its 200-day moving average price is $10.62. Y-mAbs Therapeutics has a 52-week low of $4.25 and a 52-week high of $18.19. The company has a market cap of $217.23 million, a PE ratio of -8.98 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The firm had revenue of $26.50 million during the quarter, compared to analyst estimates of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter last year, the business earned ($0.02) earnings per share. On average, analysts forecast that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Y-mAbs Therapeutics during the third quarter valued at $44,000. KLP Kapitalforvaltning AS acquired a new stake in Y-mAbs Therapeutics during the fourth quarter valued at $46,000. ProShare Advisors LLC acquired a new stake in Y-mAbs Therapeutics during the fourth quarter valued at $99,000. Intech Investment Management LLC acquired a new stake in Y-mAbs Therapeutics during the third quarter valued at $133,000. Finally, Wells Fargo & Company MN grew its position in Y-mAbs Therapeutics by 54.1% during the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock valued at $137,000 after buying an additional 6,131 shares during the period. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.